No CrossRef data available.
Article contents
Treatment of depressive syndrome in patients with psychosomatic disorders
Published online by Cambridge University Press: 16 April 2020
Abstract
We analyzed a comparative evaluation of the effectiveness of the use of the antidepressant “Zoloft” in the complex treatment of depressive syndrome in 112 patients with psychosomatic disorders. Such patients lose interest in treatment, at the same time steadfast attention to their internal condition is noticed. Very frequently in these patients under the background of low mood, great anxiety, fear concerning the condition of their health is noticed.
Taking into account the above symptoms, we included “Zoloft” in the complex pharmacotherapeutic treatment. This choice was made because “Zoloft's” possibility of taking it once in a day, high safety, lack of dependence, insignificant side effects. The average therapeutic dosage was consisted of 50 mg/day duration of use – up to 4 months.
As the results, we found the regression of depressive symptoms in 89% of patients in this group was noticed at the end of the first week from the beginning of taking the drug. At the beginning this concerned anxieties and fears; mood was raised, active desire for prolonging the treatment was noticed. Sleep at night was better, psychotherapeutic correction was adequately effective. Fast regress of somatic complains were also noticed.
Thus, the results testify to a high efficiency of the Zoloft and good compatibility with psychocorrective work. Catamnestical data of from 2 to 4 years allow us to believe in the excellence (reliability) of our results.
- Type
- Poster Session 2: Depressive Disorders
- Information
- European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S241
- Copyright
- Copyright © European Psychiatric Association 2007
Comments
No Comments have been published for this article.